Donald Wender, MD
Hematology & Oncology · Sioux City, IANPI 1861463275
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,127 of the $22,111 with a category attached, or 68.4%. It is spread thinly across 60 manufacturers, the largest accounting for just 14.8%. Reporting peaked in 2022 at $5,006 and has fallen 54.1% since, to $2,300 in 2025. Among hematology & oncology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,016 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Bristol Myers Squibb$2K
- Ipsen Biopharmaceuticals, Inc$1K
- Johnson & Johnson$1K
- E.r. Squibb & Sons, L.L.C.$975
- Seagen Inc.$929
- plus $12K from 54 others
Across 243 payments — averaging $5209.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$560K
- Pfizer$212K
- Bristol Myers Squibb$89K
- Ipsen Bioscience Inc.$61K
- E.r. Squibb & Sons, L.L.C.$58K
- Epizyme, Inc.$57K
- plus $229K from 11 others
What the payments were for
- Consulting fees$4,50020%
- Speaking & faculty fees$1151%
- Food & beverage$15,12768%
- Education$2,37011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,111 in reported general payments places this provider in the 90th percentile of 75 hematology & oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 66 | $1,167,184 |
| CalquenceAcalabrutinib Maleate | 59 | $732,040 |
| ImbruvicaIbrutinib | 40 | $611,978 |
| Lenalidomide | 43 | $554,528 |
| KisqaliRibociclib Succinate | 24 | $380,335 |
| CabometyxCabozantinib S-Malate | 14 | $321,663 |
| IbrancePalbociclib | 20 | $319,398 |
| XtandiEnzalutamide | 29 | $281,549 |
| TagrissoOsimertinib Mesylate | 17 | $239,731 |
| LynparzaOlaparib | 21 | $223,354 |
| TibsovoIvosidenib | 11 | $199,320 |
| TasignaNilotinib Hcl | 16 | $160,400 |
| BesremiRopeginterferon Alfa-2b-Njft | 11 | $159,656 |
| CreonLipase/Protease/Amylase | 15 | $32,651 |
| EliquisApixaban | 40 | $21,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso, Lynparza | $3,280 | $1,195,12597 claims |
| Bristol Myers SquibbRevlimid | $1,773 | $1,167,18466 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $94 | $611,97840 claims |
| NovartisKisqali, Tasigna | $784 | $540,73540 claims |
| PfizerIbrance, Eliquis | $556 | $341,33560 claims |
| Exelixis Inc.Cabometyx | $341 | $321,66314 claims |
| Astellas Pharma US IncXtandi | $629 | $281,54929 claims |
| Servier Pharmaceuticals LLCTibsovo | $381 | $199,32011 claims |
| Pharmaessentia USA CorporationBesremi | $233 | $159,65611 claims |
| AbbVieCreon | $512 | $32,65115 claims |
| Lilly USA, LLCOlanzapine | $444 | $1,01253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 75 hematology & oncology providers in Iowa.
Other hematology & oncology in Sioux City
- Nibash BudhathokiSioux City$5K
- Radha RaoSioux City$2K
- Chandana JavvajiSioux City$1K
- Sakeer HussainCouncil Bluffs$74K
- Usha PerepuIowa City$70K
- Umang SwamiIowa City$54K
- Umar FarooqIowa City$30K
- Brian LinkIowa City$26K
- Mark KarwalIowa City$25K
- Kartik AnandWest Des Moines$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.